USA- Moderna Inc has named former PerkinElmer executive James Mock as the company’s chief financial officer (CFO), effective Sept. 6.

After hiring Gomez, the mRNA powerhouse soon let him go after learning that his old company, the dental equipment manufacturer Dentsply Sirona, was looking into “some financial reporting concerns”.

His departure followed the announcement by his previous employer, Dentsply Sirona, that it was unable to submit its first-quarter 2022 financial report due to an internal accounting investigation.

David Meline, the moderna’s then retired CFO, took up the role in an acting capacity as the company sought for a replacement.

Mock has been the CFO of PerkinElmer, a major life sciences and diagnostics company, since 2018.

He has overseen several small acquisitions in the past year as well as a roughly US$5.3 billion acquisition of antibody and reagents company BioLegend.

Mock will report to CEO Stéphane Bancel and serve on the Moderna Executive Committee.

Recently, PerkinElmer announced plans to sell its food and business services businesses to a private equity firm for nearly US$2.5 billion. Prior to PerkinElmer, Mock worked at General Electric for almost two decades.

At PerkinElmer, Max Krakowiak, the organization’s current vice president of corporate finance, will succeed Mock.

Jamey’s expertise in growing international enterprises will guarantee that we remain in a strong position going forward. I’m eager to collaborate with Jamey and welcome him to Moderna

Stéphane Bancel, Moderna’s CEO

Tweet

“I am thrilled to join the Moderna team as they continue their inspirational and ground-breaking work in bringing the promise of mRNA to the world,” said Mr. Mock.

Stéphane Bancel, Moderna’s CEO welcomed James warmly to the Moderna Executive Committee.

He added that Moderna is at an exciting time with a developing mRNA platform, four Phase 3 trials this year, imminent proof-of-concept evidence in rare illnesses and immuno-oncology, significant commercial momentum and a solid financial position.

“Jamey’s expertise in growing international enterprises will guarantee that we remain in a strong position going forward. I’m eager to collaborate with Jamey and welcome him to Moderna,” continued Bancel.

Bancel also expressed his gratitude for David’s numerous accomplishments and stable leadership and wished him the best in his well-earned retirement.

David Meline will retire from his position as the company’s CFO effective the same date as Mr. Mock’s appointment, but he will continue to work for the company as a consultant to help with the transition.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE